Adrenomedullin, as measured as bio-ADM in the current study, showed its prognostic value regarding severity of respiratory failure, need for extracorporal organ support and 28-day mortality [21] as well as development of AKI [22] in COVID-19 patients who were admitted to ICU, but these studies are not fully comparable to the current study, which included a broader spectrum of disease severity. This evidence concerns the gene ADM and COVID-19.